Filed Pursuant to Rule 433
Registration No. 333-211317
Registration No. 333-211317-01
February 1, 2018
The information in this pricing supplement supplements the preliminary prospectus supplement, dated February 1, 2018 (the Preliminary Prospectus Supplement), and supersedes the information in the Preliminary Prospectus Supplement to the extent it is inconsistent with the information in the Preliminary Prospectus Supplement.
|$700,000,000 5.375% Junior Subordinated Notes F due 2078 (the Notes)|
|Issuer:||Enterprise Products Operating LLC (EPO)|
|Guarantee:||The Notes will be unconditionally guaranteed on a subordinated basis by Enterprise Products Partners L.P.|
Baa2 by Moodys Investors Service, Inc.
BBB- by S&P Global Ratings
BBB- by Fitch Ratings Inc.
|Trade Date:||February 1, 2018|
|Expected Settlement Date:||February 15, 2018 (T+10)|
|Note Type:||Junior Subordinated Notes|
|Legal Format:||SEC Registered|
|Price to Public:||100.000%|
|Maturity Date:||February 15, 2078|
|Interest Rate During Fixed Rate Period:||5.375% up to, but not including, February 15, 2028|
|Interest Rate During Floating Rate Period:||From, and including, February 15, 2028, at a floating rate based on three month LIBOR, plus 257 basis points, reset quarterly|
|Optional Deferral:||Up to 10 consecutive years per deferral|
|Optional Redemption:||Redeemable, in whole or in part, on or after February 15, 2028 at 100% of the principal amount, plus any accrued or unpaid interest|
|Call for Tax Event:||Prior to February 15, 2028, at any time at 100% of the principal amount, plus any accrued and unpaid interest|
|Call for Rating Agency Event:||Prior to February 15, 2028, at any time at 102% of the principal amount, plus any accrued and unpaid interest|
|Interest Payment Dates During Fixed Rate Period:||Semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2018|
|Interest Payment Dates During Floating Rate Period:||Quarterly in arrears on February 15, May 15, August 15 and November 15 of each year, beginning on May 15, 2028|
|CUSIP/ISIN:||29379VBR3 / US29379VBR33|
|Use of Proceeds:||EPO will receive aggregate net proceeds of approximately $691,760,000 from the sale of the notes to the underwriters after deducting the underwriting discount and other estimated offering expenses payable by EPO. EPO expects to use the net proceeds of this offering, together with the proceeds from the concurrent senior notes offering (as defined in the Preliminary Prospectus Supplement), if completed, for the repayment of debt, including the repayment of amounts outstanding under our commercial paper program and the repurchase or redemption of all or a portion of the Junior Subordinated Notes B (as defined in the Preliminary Prospectus Supplement), and for general company purposes.|
|Joint Book-Running Managers:|| |
J.P. Morgan Securities LLC
Merrill Lynch, Pierce, Fenner & Smith
Deutsche Bank Securities Inc.
Scotia Capital (USA) Inc.
DNB Markets, Inc.
Morgan Stanley & Co. LLC
SG Americas Securities, LLC
TD Securities (USA) LLC
|Senior Co-Manager:||BBVA Securities Inc.|
Barclays Capital Inc.
Citigroup Global Markets Inc.
Credit Suisse Securities (USA) LLC
Mizuho Securities USA Inc.
RBC Capital Markets, LLC
Sumitomo Mitsui Banking Corporation
SunTrust Robinson Humphrey, Inc.
The Bank of Tokyo-Mitsubishi UFJ, Ltd.
U.S. Bancorp Investments, Inc.
Wells Fargo Securities, LLC
* Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
Modifications to the Preliminary Prospectus Supplement:
The following sentence on page S-3 is completed as follows: We estimate that we will receive net proceeds of approximately $1.981 billion from the concurrent senior notes offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
In the As Adjusted column of the September 30, 2017 capitalization table, the following line items are updated to reflect the assumed application of net proceeds from this offering and the concurrent senior notes offering at that date (unaudited): cash and cash equivalents is $115.4 million; Commercial Paper Notes, variable rates is $0 million; Enterprise Senior Notes TT is completed as followsSenior Notes TT, 2.800% fixed-rate, due February 15, 2021(4)$750.0 million; Enterprise Senior Notes UU is completed as followsSenior Notes UU, 4.250% fixed-rate, due February 15, 2048(4)$1,250.0 million; Enterprise Junior Subordinated Notes B, fixed/variable-rate, due January 2069 is $0 million; EPO Junior Subordinated Notes F is hereby completed as followsEPO Junior Subordinated Notes F, fixed/variable-rate, due February 15, 2075$700.0 million; total principal amount of senior and junior debt obligations is $25,041.7 million; total other, non-principal amounts is $231.4 million; total debt obligations, including current maturities is $24,810.3 million; and total debt and equity is $47,351.3 million.
The following replaces the last two sentences under the subheading Notice to Prospective Investors in the European Economic Area:
This prospectus supplement and the accompanying prospectus have been prepared on the basis that any offer of notes in any Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State) will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of notes. Accordingly any person making or intending to make an offer in that Relevant Member State of notes which are the subject of the offering contemplated in this prospectus supplement and the accompanying prospectus may only do so in circumstances in which no obligation arises for the Issuer or the Manager to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the Issuer nor the Manager have authorized, nor do they authorize, the making of any offer of notes in circumstances in which an obligation arises for the Issuer or the Manager to publish a prospectus for such offer. The expression Prospectus Directive means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.
The following replaces the language under the subheading Notice to Prospective Investors in the United Kingdom:
The communication of this prospectus supplement, the accompanying prospectus and any other document or materials relating to the issue of the notes offered hereby is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdoms Financial Services and Markets Act 2000, as amended (the FSMA). Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom who have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Financial Promotion Order)), or who fall within Article 49(2)(a) to (d) of the Financial Promotion Order, or who are any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order (all such persons together being referred to as relevant persons). In the United Kingdom, the notes offered hereby are only available to, and any investment or investment activity to which this prospectus supplement and the accompanying prospectus relate will be engaged in only with, relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this prospectus supplement, the accompanying prospectus or any of their contents.
Any invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) in connection with the issue or sale of the notes may only be communicated or caused to be communicated in circumstances in which Section 21(1) of the FSMA does not apply to the Issuer.
All applicable provisions of the FSMA must be complied with in respect to anything done by any person in relation to the notes in, from or otherwise involving the United Kingdom.
All information presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by the changes described herein.
The Issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the SEC) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting the SECs website at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling J.P. Morgan Securities LLC at 1-212- 834-4533, Merrill Lynch, Pierce, Fenner & Smith Incorporated at 1-800-294-1322, Deutsche Bank Securities Inc. at 1-800-503-4611 or Scotia Capital (USA) Inc. at 1-800-372-3930.